A standardized extract of cultured <em>Lentinula edodes</em> mycelia downregulates cortactin in gemcitabine‑resistant pancreatic cancer cells

Islam,Shajedul; Kitagawa,Takao; Baron,Byron; Kuhara,Keisuke; Nagayasu,Hiroki; Kobayashi,Masanobu; Chiba,Itsuo; Kuramitsu,Yasuhiro

doi:10.3892/ol.2021.12915

A standardized extract of cultured Lentinula edodes mycelia downregulates cortactin in gemcitabine‑resistant pancreatic cancer cells

Authors:
- Shajedul Islam
- Takao Kitagawa
- Byron Baron
- Keisuke Kuhara
- Hiroki Nagayasu
- Masanobu Kobayashi
- Itsuo Chiba
- Yasuhiro Kuramitsu
View Affiliations

Affiliations: Advanced Research Promotion Center, Health Sciences University of Hokkaido, Ishikari‑Tobetsu, Hokkaido 061‑0293, Japan, Faculty of Medicine and Surgery, Centre for Molecular Medicine and Biobanking, University of Malta, Msida, MSD 2080, Malta, Division of Oral and Maxillofacial Surgery, Department of Human Biology and Pathophysiology, School of Dentistry, Health Sciences University of Hokkaido, Ishikari‑Tobetsu, Hokkaido 061‑0293, Japan, Division of Disease Control and Molecular Epidemiology, Department of Oral Growth and Development, School of Dentistry, Health Sciences University of Hokkaido, Ishikari‑Tobetsu, Hokkaido 061‑0293, Japan
Published online on: July 9, 2021 https://doi.org/10.3892/ol.2021.12915
Article Number: 654

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

AHCC^®, a standardized extract of cultured Lentinula edodes mycelia, enhances the therapeutic effects and reduces the adverse effects of chemotherapy. Our previous study reported that treatment with AHCC^® downregulated the expression levels of tumor‑associated proteins in the gemcitabine‑resistant pancreatic cancer cell line, KLM1‑R. However, to the best of our knowledge, the role of AHCC^® in the inhibition of cell migration remains unexplored. Cortactin (CTTN), an actin nucleation‑promoting factor, has been reported to be upregulated and correlated with migration, invasion and metastasis in pancreatic cancer cells. The present study aimed to investigate the effects of AHCC^® on cell migration and the protein expression level of CTTN in KLM1‑R cells. The Gene Expression Profiling Interactive Analysis (GEPIA2), an online bioinformatics platform, was used to analyze CTTN mRNA expression levels in pancreatic cancer tissues compared with normal pancreatic tissues. CTTN mRNA expression and its association with clinicopathological characteristics were assessed by using the GEPIA2 platform. Next, the effects of AHCC^® on KLM1‑R cell migration were investigated by in vitro wound‑healing assay. The KLM1‑R cells were treated with AHCC^® at a concentration of 10 mg/ml for 48 h. Western blotting was performed on of cell lysates with anti‑CTTN or anti‑actin antibodies to assess the protein expression levels of CTTN. Bioinformatics analysis indicated that the mRNA expression level of CTTN increased in pancreatic cancer tissues. The increased mRNA expression levels of CTTN were inversely associated with clinicopathological characteristics, including disease stages and prolonged patient survival times. The administration of 10 mg/ml AHCC^® significantly inhibited KLM1‑R cells migration compared with controls. The protein expression levels of CTTN were significantly reduced in AHCC^®‑treated KLM1‑R cells, whereas actin expression was not affected. The downregulation of CTTN indicated the anti‑metastatic potential of AHCC^® in pancreatic cancer cells. Overall, AHCC^® may have the potential to be a complementary and alternative therapeutic approach in treating pancreatic cancer.

View Figures

View References

1	Islam S, Kitagawa T, Baron B, Abiko Y, Chiba I and Kuramitsu Y: ITGA2, LAMB3, and LAMC2 may be the potential therapeutic targets in pancreatic ductal adenocarcinoma: An integrated bioinformatics analysis. Sci Rep. 11:105632021. View Article : Google Scholar : PubMed/NCBI
2	Amrutkar M and Gladhaug IP: Pancreatic cancer chemoresistance to gemcitabine. Cancers (Basel). 9:1572017. View Article : Google Scholar : PubMed/NCBI
3	Yamaguchi H and Condeelis J: Regulation of the cytoskeleton in cancer cell migration and invation. Biochim Biophys Acta. 1773:642–652. 2007. View Article : Google Scholar : PubMed/NCBI
4	Yin M, Ma W and An L: Cortactin in cancer cell migration and invasion. Oncotarget. 8:88232–88243. 2017. View Article : Google Scholar : PubMed/NCBI
5	Kamiyama Y, Matsui Y, Kawaguchi Y, Kosuna K and Wakame K: Active hexose correlated compound (AHCC). Biotherapy. 14:959–964. 2000.
6	Kidd P: The use of mushroom glucans and proteoglycans in cancer treatment. Altern Med Rev. 5:4–27. 2000.PubMed/NCBI
7	Ye SF, Ichimura K, Wakame K and Ohe M: Suppressive effects of active hexose correlated compound on the increased activity of hepatic and renal ornithine decarboxylase induced by oxidative stress. Life Sci. 74:593–602. 2003. View Article : Google Scholar : PubMed/NCBI
8	Kuhara K, Tokuda K, Kitagawa T, Baron B, Tokunaga M, Harada K, Terasaki M, Uehara O, Ohta T, Takai R, et al: CUB domain-containing protein 1 (CDCP1) is down-regulated by active hexose-correlated compound in human pancreatic cancer cells. Anticancer Res. 38:6107–6111. 2018. View Article : Google Scholar : PubMed/NCBI
9	Suenaga S, Kuramitsu Y, Kaino S, Maehara S-I, Maehara Y, Sakaida I and Nakamura K: Active hexose-correlated compound down-regulates HSP27 of pancreatic cancer cells, and helps the cytotoxic effect of gemcitabine. Anticancer Res. 34:141–146. 2014.PubMed/NCBI
10	Tokunaga M, Baron B, Kitagawa T, Tokuda K and Kuramitsu Y: Active hexose-correlated compound down-regulates heat shock factor 1, a transcription factor for HSP27, in gemcitabine-resistant human pancreatic cancer cells. Anticancer Res. 35:6063–6067. 2015.PubMed/NCBI
11	Nawata J, Kuramitsu Y, Wang Y, Kitagawa T, Tokuda K, Baron B, Akada J, Suenaga S, Kaino S, Maehara S, et al: Active hexose-correlated compound down-regulates sex-determining region Y-box 2 of pancreatic cancer cells. Anticancer Res. 34:4807–4811. 2014.PubMed/NCBI
12	Mori-Iwamoto S, Kuramitsu Y, Ryozawa S, Mikuria K, Fujimoto M, Maehara S, Maehara Y, Okita K, Nakamura K and Sakaida I: Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine. Int J Oncol. 31:1345–1350. 2007.PubMed/NCBI
13	Tang Z, Kang B, Li C, Chen T and Zhang Z: GEPIA2: An enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 47:W556–W560. 2019. View Article : Google Scholar : PubMed/NCBI
14	Maehara S, Tanaka S, Shimada M, Shirabe K, Saito Y, Takahashi K and Maehara Y: Selenoprotein P, as a predictor for evaluating gemcitabine resistance in human pancreatic cancer cells. Int J Cancer. 112:184–189. 2004. View Article : Google Scholar : PubMed/NCBI
15	Belkourchia F and Desrosiers R: The enzyme L-isoaspartyl (D-aspartyl) methyltransferase promotes migration and invasion in human U-87 MG and U-251 MG glioblastoma cell lines. Biomed Pharmacother. 140:1117662021. View Article : Google Scholar : PubMed/NCBI
16	Schneider CA, Rasband WS and Eliceiri KW: NIH image to ImageJ: 25 years of image analysis. Nat Methods. 9:671–675. 2012. View Article : Google Scholar : PubMed/NCBI
17	Islam S, Uehara O, Matsuoka H, Kuramitsu Y, Adhikari BR, Hiraki D, Toraya S, Jayawardena A, Saito I, Muthumala M, et al: DNA hypermethylation of sirtuin 1 (SIRT1) caused by betel quid chewing-a possible predictive biomarker for malignant transformation. Clin Epigenetics. 12:122020. View Article : Google Scholar : PubMed/NCBI
18	Matsushita K, Kuramitsu Y, Ohiro Y, Obara M, Kobayashi M, Li YQ and Hosokawa M: Combination therapy of active hexose correlated compound plus UFT significantly reduces the metastasis of rat mammary adenocarcinoma. Anticancer Drugs. 9:343–350. 1998. View Article : Google Scholar : PubMed/NCBI
19	Cowawintaweewat S, Manoromana S, Sriplung H, Khuhaprema T, Tongtawe P, Tapchaisri P and Chaicumpa W: Prognostic improvement of patients with advanced liver cancer after active hexose correlated compound (AHCC) treatment. Asian Pac J Allergy Immunol. 24:33–45. 2006.PubMed/NCBI
20	Hunter RJ, Fujii H, Wakame K, Gaikwad A, Wolf JK and Smith JA: Evaluation of active hexose correlated compound (AHCC) in combination with pegylated liposomal doxorubicin for treatment of ovarian cancer. Int J Appl Res Nat Prod. 4:6–11. 2011.
21	Hangai S, Iwase S, Kawaguchi T, Kogure Y, Miyaji T, Matsunaga T, Nagumo Y and Yamaguchi T: Effect of active hexose-correlated compound in women receiving adjuvant chemotherapy for breast cancer: A retrospective study. J Altern Complement Med. 19:905–910. 2013. View Article : Google Scholar : PubMed/NCBI
22	Haidari M, Zhang W and Wakame K: Disruption of endothelial adherens junction by invasive breast cancer cells is mediated by reactive oxygen species and is attenuated by AHCC. Life Sci. 93:994–1003. 2013. View Article : Google Scholar : PubMed/NCBI
23	Ito T, Urushima H, Sakaue M, Yukawa S, Honda H, Hirai K, Igura T, Hayashi N, Maeda K, Kitagawa T and Kondo K: Reduction of adverse effects by a mushroom product, active hexose correlated compound (AHCC) in patients with advanced cancer during chemotherapy-the significance of the levels of HHV-6 DNA in saliva as a surrogate biomarker during chemotherapy. Nutr Cancer. 66:377–382. 2014. View Article : Google Scholar : PubMed/NCBI
24	Ignacio RM, Kim CS, Kim YD, Lee HM, Qi XF and Kim SK: Therapeutic effect of active hexose-correlated compound (AHCC) combined with CpG-ODN (oligodeoxynucleotide) in B16 melanoma murine model. Cytokine. 76:131–137. 2015. View Article : Google Scholar : PubMed/NCBI
25	Cao Z, Chen X, Lan L, Zhang Z, Du J and Liao L: Active hexose correlated compound potentiates the antitumor effects of low-dose 5-fluorouracil through modulation of immune function in hepatoma 22 tumor-bearing mice. Nutr Res Pract. 9:129–136. 2015. View Article : Google Scholar : PubMed/NCBI
26	Yanagimoto H, Satoi S, Yamamoto T, Hirooka S, Yamaki S, Kotsuka M, Ryota H, Michiura T, Inoue K, Matsui Y, et al: Alleviating effect of active hexose correlated compound (AHCC) on chemotherapy-related adverse events in patients with unresectable pancreatic ductal adenocarcinoma. Nutr Cancer. 68:234–240. 2016. View Article : Google Scholar : PubMed/NCBI
27	Graham ÉA, Mallet JF, Jambi M, Nishioka H, Homma K and Matar C: MicroRNA signature in the chemoprevention of functionally-enriched stem and progenitor pools (FESPP) by active hexose correlated compound (AHCC). Cancer Biol Ther. 18:765–774. 2017. View Article : Google Scholar : PubMed/NCBI
28	Fatehchand K, Santhanam R, Shen B, Erickson EL, Gautam S, Elavazhagan S, Mo X, Belay T, Tridandapani S and Butchar JP: Active hexose-correlated compound enhances extrinsic-pathway-mediated apoptosis of acute myeloid leukemic cells. PLoS One. 12:e01817292017. View Article : Google Scholar : PubMed/NCBI
29	Choi JY, Lee S, Yun SM, Suh DH, Kim K, No JH, Jeong EH and Kim YB: Active hexose correlated compound (AHCC) inhibits the proliferation of ovarian cancer cells by suppressing signal transducer and activator of transcription 3 (STAT3) activation. Nutr Cancer. 70:109–115. 2018. View Article : Google Scholar : PubMed/NCBI
30	Suknikhom W, Lertkhachonsuk R and Manchana T: The effects of active hexose correlated compound (AHCC) on levels of CD4+ and CD8+ in patients with epithelial ovarian cancer or peritoneal cancer receiving platinum based chemotherapy. Asian Pac J Cancer Prev. 18:633–638. 2017.PubMed/NCBI
31	Buday L and Downward J: Roles of cortactin in tumor pathogenesis. Biochim Biophys Acta. 1775:263–273. 2007.PubMed/NCBI
32	Ammer AG and Weed S: Cortactin branches out: Roles in regulating protrusive actin dynamics. Cell Motil Cytoskeleton. 65:687–707. 2008. View Article : Google Scholar : PubMed/NCBI
33	He J, Xia TS and Wang S: Cortactin and tumor invasiveness. Chin J Cancer Prev Treat. 22:72–75, 80. 2015.
34	Stock K, Borrink R, Mikesch JH, Hansmeier A, Rehkämper J, Trautmann M, Wardelmann E, Hartmann W, Sperveslage J and Steinestel K: Overexpression and Tyr421-phosphorylation of cortactin is induced by three-dimensional spheroid culturing and contributes to migration and invasion of pancreatic ductal adenocarcinoma (PDAC) cells. Cancer Cell Int. 19:772019. View Article : Google Scholar : PubMed/NCBI
35	Patel AS, Schlechter GL, Wasilenko WJ and Somers KD: Overexpression of EMS1/cortactin in NIH3T3 fibroblasts causes increased cell motility and invasion in vitro. Oncogene. 16:3227–3232. 1998. View Article : Google Scholar : PubMed/NCBI
36	Huang C, Liu J, Haudenschild CC and Zhan X: The role of tyrosine phosphorylation of cortactin in the locomotion of endothelial cells. J Biol Chem. 273:25770–25776. 1998. View Article : Google Scholar : PubMed/NCBI
37	Tehrani S, Tomasevic N, Weed S, Sakowicz R and Cooper J: Src phosphorylation of cortactin enhances actin assembly. Proc Natl Acad Sci USA. 104:11933–11938. 2007. View Article : Google Scholar : PubMed/NCBI
38	Head JA, Jiang D, Li M, Zorn LJ, Schaefer EM, Parsons JT and Weed SA: Cortactin tyrosine phosphorylation requires Rac1 activity and association with the cortical actin cytoskeleton. Mol Biol Cell. 14:3216–3229. 2003. View Article : Google Scholar : PubMed/NCBI
39	Bowden ET, Onikoyi E, Tidwell R, Myoui A, Yoneda T, Yamada KM and Mueller SC: Co-localization of cortactin and phosphotyrosine identifies active invadopodia in human breast cancer cells. Exp Cell Res. 312:1240–1253. 2006. View Article : Google Scholar : PubMed/NCBI
40	Wu C, Sun M, Liu L and Zhou W: The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene. 306:1–12. 2003. View Article : Google Scholar : PubMed/NCBI
41	Frank C, Burkhardt C, Imhof D, Ringel J, Zschörnig O, Wieligmann K, Zacharias M and Böhmer FD: Effective dephosphorylation of Src substrates by SHP-1. J Biol Chem. 279:11375–11383. 2004. View Article : Google Scholar : PubMed/NCBI